Floatz logo

Ranitidine

Monoclonal Paraproteinemia Disease

Hellenic Society of HematologySmall moleculePhase 2Active
CCC
53/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
38/ 100
Competitive Position
89/ 100

Competitive context

12 Active assets in the Monoclonal Paraproteinemia Disease cohort.

Asset / SponsorPhaseRating
Lenalidomide
Hellenic Society of Hematology
Phase 3BB
Pomalidomide
Hellenic Society of Hematology
Phase 2B
Dexasone
Hellenic Society of Hematology
Phase 2B
Humax-Cd20
M.D. Anderson Cancer Center
Phase 2B
Diphenhydramine
Hellenic Society of Hematology
Phase 2CCC

View all 14 →

Same molecule, other indications

Ranitidine is also rated in:

breast cancerActive
BB
Indicative · Phase 2/3
64 / 100
View asset →
relapsing-remitting multiple sclerosisDormant
B
Indicative · Phase 4
63 / 100
View asset →
plasma cell myelomaActive
B
Indicative · Phase 3
62 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →